Almirall SA | ALM

Almirall SA traded at 8.71 this Friday March 24th, decreasing 0.06 or 0.68 percent since the previous trading session. Looking back, over the last four weeks, Almirall SA lost 4.18 percent. Over the last 12 months, its price fell by 30.25 percent. Looking ahead, we forecast Almirall SA to be priced at 8.44 by the end of this quarter and at 7.71 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
8.71
Daily Change
-0.68%
Yearly
-30.25%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Amadeus IT 57.76 -0.96 -1.63% 2.05%
Cie Automotive 24.92 -0.38 -1.50% 24.10%
Ence Energia y Celulosa SA 3.37 -0.17 -4.69% 1.75%
Genmab 2,578.00 28.00 1.10% 8.59%
GRIFOLS 8.70 -0.31 -3.48% -43.79%
Inditex 29.08 -0.58 -1.96% 39.81%
Lonza Group 529.00 -9.80 -1.82% -19.19%
Melia Hotels 5.38 -0.15 -2.71% -18.48%
Orion 41.67 0.12 0.29% 3.84%
Recordati 38.82 0.13 0.34% -14.49%
Tecnicas Reunidas 9.48 -0.58 -5.72% 10.17%
UCB 79.08 0.20 0.25% -26.20%
Viscofan 68.05 -0.10 -0.15% 29.62%


Almirall SA
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.